2. Academic Validation
  3. Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis

Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis

  • J Med Chem. 2019 Feb 14;62(3):1180-1202. doi: 10.1021/acs.jmedchem.8b01218.
Michael G Thomas 1,  Manu De Rycker 1,  Myriam Ajakane 2,  Sébastian Albrecht 1,  Ana Isabel Álvarez-Pedraglio 3,  Markus Boesche 2,  Stephen Brand 1,  Lorna Campbell 1,  Juan Cantizani-Perez 3,  Laura A T Cleghorn 1,  Royston C B Copley 4,  Sabrinia D Crouch 3,  Alain Daugan 5,  Gerard Drewes 2,  Santiago Ferrer 3,  Sonja Ghidelli-Disse 2,  Silvia Gonzalez 3,  Stephanie L Gresham 6,  Alan P Hill 4,  Sean J Hindley 4,  Rhiannon M Lowe 6,  Claire J MacKenzie 1,  Lorna MacLean 1,  Sujatha Manthri 1,  Franck Martin 5,  Juan Miguel-Siles 3,  Van Loc Nguyen 5,  Suzanne Norval 1,  Maria Osuna-Cabello 1,  Andrew Woodland 1,  Stephen Patterson 1,  Imanol Pena 3,  Maria Teresa Quesada-Campos 3,  Iain H Reid 4,  Charlotte Revill 1,  Jennifer Riley 1,  Jose Ramon Ruiz-Gomez 3,  Yoko Shishikura 1,  Frederick R C Simeons 1,  Alasdair Smith 1,  Victoria C Smith 1,  Daniel Spinks 1,  Laste Stojanovski 1,  John Thomas 1,  Stephen Thompson 1,  Tim Underwood 4,  David W Gray 1,  Jose M Fiandor 3,  Ian H Gilbert 1,  Paul G Wyatt 1,  Kevin D Read 1,  Timothy J Miles 3
Affiliations

Affiliations

  • 1 Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences , University of Dundee , Dundee DD1 5EH , U.K.
  • 2 Cellzome GmbH , A GlaxoSmithKline Company , Meyerhofstrasse 1 , 69117 Heidelberg , Germany.
  • 3 Global Health R&D , GlaxoSmithKline , Calle Severo Ochoa, 2 , 28760 Tres Cantos , Madrid Spain.
  • 4 Platform Technology & Science , GlaxoSmithKline Medicines Research Centre , Gunnels Wood Road , Stevenage , Hertfordshire SG1 2NY , U.K.
  • 5 Centre de Recherche , GlaxoSmithKline , Les Ulis, 25,27 Avenue du Québec , 91140 Villebon sur Yvette France.
  • 6 Platform Technology & Science , GlaxoSmithKline , David Jack Centre for R&D, Park Road , Ware , Hertfordshire SG12 0DP , U.K.
PMID: 30570265 DOI: 10.1021/acs.jmedchem.8b01218
Abstract

The leishmaniases are diseases that affect millions of people across the world, in particular visceral leishmaniasis (VL) which is fatal unless treated. Current standard of care for VL suffers from multiple issues and there is a limited pipeline of new candidate drugs. As such, there is a clear unmet medical need to identify new treatments. This paper describes the optimization of a phenotypic hit against Leishmania donovani, the major causative organism of VL. The key challenges were to balance solubility and metabolic stability while maintaining potency. Herein, strategies to address these shortcomings and enhance efficacy are discussed, culminating in the discovery of preclinical development candidate GSK3186899/DDD853651 (1) for VL.

Figures
Products